NVDA Regains $217 but Trails Peers as Earnings Loom

NVIDIA closed Tuesday at $217.94, up less than 1% on the day and roughly 0.7% on the week, a recovery from the $210.96 low reported in Monday's stock note but still lagging the 1.5% median gain posted by its closest correlated peers. AMD added 4.8% over the same five sessions. POET Technologies gained 2.3%. Even the smaller names in the peer group moved faster. The stock has bounced from its mid-October trough, but it has not yet closed the gap opened by the previous month's 3.2% decline.

The most notable development this week is the sharp jump in cost to borrow. It more than doubled over seven days to 0.27%, up 137% week-on-week. That sounds alarming until context is applied. The absolute level is still very low by any standard, and the borrow market remains exceptionally loose. Availability is essentially uncapped, with more than 23 billion shares available to borrow against roughly 305 million shares short. Short interest itself edged down 2.3% over the week to 1.25% of free float. That is a low and non-threatening level. The cost-to-borrow spike reflects noise in the lending pool rather than a directional build in short conviction. The ORTEX short score of 30.3 has been virtually flat for the past two weeks, consistent with that reading. Options positioning has also normalised. The put/call ratio of 1.02 is close to its 20-day average of 0.99, with a z-score of just 0.32. The peak hedging pressure seen on October 15, when the PCR hit 1.22, its highest reading of the past year, has unwound. Positioning looks relaxed rather than charged.

The Street remains firmly constructive, though targets sit well above where the stock is trading. The mean price target from analysts is $328.95, implying roughly 51% upside from current levels. Recent activity has been dominated by reiterations rather than fresh moves. Needham held its Buy and $300 target on October 22. Cantor Fitzgerald and Rosenblatt have both stood pat at Overweight/Buy with targets of $350 and $390 respectively. The most recent target upgrades of note came in late August, after the last earnings print, when JP Morgan raised to $320 from $280 and Bernstein moved to $400 from $315 following a strong quarterly beat. EPS momentum ranks in the 82nd percentile over 90 days, and the stock scores in the 74th percentile on earnings yield. The valuation is not cheap: the price-to-earnings multiple at 14.8x forward earnings has compressed about 1.5 points over the past month, partly unwinding the premium built in during September's AI infrastructure enthusiasm. EV/EBITDA has also drifted lower, down 0.6 points over 30 days. The bear case centres on custom ASIC competition from Google TPUs and Amazon Trainium, potential China embargo tightening, and gross margin pressure from inventory charges as Blackwell and Rubin ramp.

Retail attention has retreated sharply relative to NVIDIA's own recent history. Wikipedia pageviews, tracked daily by the Wikimedia Foundation, are running at a z-score of minus 3.1 against the prior 90 days. That is a meaningful fall in ambient retail interest. It does not carry measured predictive value for the company's financials, but it does suggest the stock is no longer commanding the reflexive attention it attracted during peak AI hype cycles. For a company whose narrative is heavily retail-driven at the margin, low visibility weeks can extend the consolidation phase.

The institutional register is orderly. BlackRock added 16.4 million shares in the quarter to September 30, lifting its stake to 8.0% of shares outstanding. FMR added 31.2 million shares in the same period, taking its holding to 3.9%. CEO Jensen Huang transferred 438,000 shares on September 17 under no disclosed 10b5-1 plan, a transaction coded as a gift rather than an open-market sale, and carries limited signalling weight. The more material open-market activity came from director Mark Stevens, who sold 1.37 million shares on September 18 for roughly $300 million, without the shelter of a pre-arranged trading plan. That is worth noting as the only sizeable discretionary disposal in the recent insider register.

The November 17 earnings date is now 20 days out. The last two quarters produced starkly different tape reactions: August's result delivered a 7% one-day gain and held most of it through the following week, while the prior print saw a 1.3% decline on the day and a 4.6% five-day slide. The setup heading into November is a stock trading 33% below the consensus analyst target, with low short interest, loose borrow, normalised options hedging, and a peer group that has outrun it on a year-to-date basis by a wide margin. The specific thing to watch between now and November 17 is whether the PCR climbs back toward the 1.2 zone it touched in mid-October as the print approaches, and whether any of the major houses with targets above $350 shift their stance ahead of the call.